Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Tang, F; Zheng, P

Tang, F (reprint author), Univ Maryland, Sch Med, Div Immunotherapy, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA.

CELL AND BIOSCIENCE, 2018; 8 ():

Abstract

Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of cancers. PD-L1 is constitut......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索